

Application number
2361537

Type(s)
Standard Characters

Category
Trademark

CIPO Status
ADVERTISED

TM5 status
LIVE/APPLICATION/
Published for Opposition



A pending trademark application has been examined by the Office and has been published in a way that provides an opportunity for the public to oppose its registration.

Filed
2024-11-12

Applicant
Teva Pharmaceutical
Industries Ltd.
124 Dvora HaNevi'a St.
Tel Aviv, 6944020
ISRAEL

Agent
OSLER, HOSKIN &
HARCOURT LLP
Suite 320, World Exchange
Plaza
100 Queen Street
Ottawa,
ONTARIO K1P1J9

Documents
[View documents](#)

Action History

Action	Action date	Due date	Comments

Index headings

XOZYRLI

Goods (Nice class & Statement)

5 (1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, menopause, ophthalmic disorders and diseases, and pain; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations for the treatment of asthma, chronic rhinosinusitis, chronic spontaneous urticaria, and food allergies; cardiovascular pharmaceuticals; pharmaceutical preparations for the prevention and treatment of endocrine diseases and disorders, namely, growth and thyroid disorders; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of psychological disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders, and psychoses.

Filed	2024-11-12		
Created	2024-11-12		
Formalized	2024-11-12		
Pre-Assessment Letter Sent	2024-11-28		Goods or Services Not Acceptable
Search Recorded	2025-09-02		
Examiner's First Report	2025-09-02	2026-03-02	
Approved	2026-06-10		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2026-06-10		APPROVED BY PROGRAM EX200M1
Advertised	2026-08-26		Vol.73 Issue 3748